A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

NCT06894212 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

522

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: SEP-363856
OTHER: Placebo

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.